Epstein–Barr virus‐associated risk factors for post‐transplant lymphoproliferative disease in pediatric liver transplant recipients

Background Post‐transplant lymphoproliferative disorder (PTLD) are the most common de novo malignancies after liver transplantation (LT) in children. The aim of our study was to assess the role of pre‐LT EBV status and post‐LT EBV viral load as risk factors for developing PTLD in a cohort of pediatr...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2022-09, Vol.26 (6), p.e14292-n/a
Main Authors: Quintero Bernabeu, Jesus, Juamperez, Javier, Mercadal‐Hally, Maria, Larrarte King, Mauricio, Gallego Melcon, Soledad, Gros Subias, Luis, Sábado Álvarez, Constantino, Soler‐Palacin, Pere, Melendo Pérez, Susana, Esperalba, Juliana, Navarro Jiménez, Alexandra, Garrido Pontnou, Marta, Camacho Soriano, Jessica, Hidalgo Llompart, Ernest, Bilbao Aguirre, Itxarone, Charco Torra, Ramón
Format: Article
Language:English
Subjects:
Epstein-Barr virus
Epstein–Barr virus infection
Hodgkin's lymphoma
Hyperplasia
Immunoproliferative diseases
Immunotherapy
Liver diseases
Liver transplantation
Liver transplants
Lymphocytes
Monoclonal antibodies
Patients
PCR
pediatric liver transplantation
Pediatrics
Posttransplant lymphoproliferative disorders
post‐transplant lymphoproliferative
Risk factors
rituximab
Targeted cancer therapy
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Post‐transplant lymphoproliferative disorder (PTLD) are the most common de novo malignancies after liver transplantation (LT) in children. The aim of our study was to assess the role of pre‐LT EBV status and post‐LT EBV viral load as risk factors for developing PTLD in a cohort of pediatric LT recipients. Methods Data of all children who underwent LT between January 2002 and December 2019 were collected. Two cohorts were built EBV pre‐LT primary infected cohort and EBV post‐LT primary infected cohort. Moreover, using the maximal EBV viral load, a ROC curve was constructed to find a cutoff point for the diagnosis of PTLD. Results Among the 251 patients included in the study, fifteen PTLD episodes in 14 LT recipients were detected (2 plasmacytic hyperplasia, 10 polymorphic PTLD, 2 monomorphic PTLD, and 1 Classical‐Hodgkin's lymphoma). Patients of the EBV post‐LT primary infected cohort were 17.1 times more likely to develop a PTLD than patients of the EBV pre‐LT primary infected cohort (2.2–133.5). The EBV viral load value to predict PTLD was set at 211 000 UI/mL (93.3% sensitivity and 77.1% specificity; AUC 93.8%; IC 0.89–0.98). In EBV post‐LT primary infected cohort, patients with a viral load above 211 000 were 30 times more likely to develop PTLD than patients with a viral load below this value (OR 29.8; 3.7–241.1; p 
ISSN:1397-3142
1399-3046
DOI:10.1111/petr.14292